Polycystic ovary syndrome (PCOS) is a heterogeneous disease entity affecting a significant percentage of women of childbearing age. It is believed that PCOS occurs in approximately 10% of women of reproductive age. In its classic form, this syndrome was first described by Stein and Leventhal in 1935, who observed the co-occurrence of amenorrhea and accompanying hirsutism, obesity and ovarian enlargement. The definition and diagnostic criteria for PCOS were proposed as late as in 1990 [1]. Diagnostic criteria for PCOS include: absence of ovulation, menstrual disorders of oligo/amenorrhea type and/or biochemical symptoms of hyperandrogenism. An important element of PCOS diagnosis is the exclusion of other clinical syndromes of the similar clinical picture, such as: androgen-secreting tumors, late revealing metabolic blocks of steroidogenesis or hypercortisolism. In 2003, the existing criteria for PCOS diagnosis were modified. The criteria added to the existing criteria included a typical ovarian picture identified by ultrasound examination, determined as: increase in the field and volume of ovaries, increase in the roundness coefficient of the ovary (ovarian width/ovarian length), the presence of microcysts having dimensions below 10 mm in a number higher than 11. Despite the prevalence of this endocrinopathy, the pathogenesis of PCOS still remains questionable and is not fully understood. In recent years, the significant role of insulin in the pathogenesis of PCOS has been emphasized. The coexistence of genetic syndromes of insulin resistance and hyperandrogenism, frequent occurrence of glucose tolerance disorders in women with PCOS and efficacy of the treatment, leading to increased sensitivity to insulin in the treatment of symptoms of PCOS, constitute indirect evidence for the participation of insulin in the pathogenesis of PCOS. Insulin resistance may be present in both lean and obese women with PCOS, and thus it is not directly related to body mass. As a result of years of intensive scientific work aimed at identifying the gene, it has been established that in the study population, a relationship between several polymorphisms (SNPs, single nucleotide polymorphisms) of the calpain 10 gene, a representative of a large family of cytoplasmic proteases, and development of carbohydrate metabolism disorders, including diabetes, exists. The risk of developing type 2 diabetes is not associated with a variant of a single polymorphism of the gene, but rather results from the haplotypes created by alleles of three SNPs, which have been numbered 19, 43, 63. This paper is a summary of recent reports on the presence of the relationship between a single nucleotide polymorphism of the calpain gene and the development of glucose metabolism disturbances in patients with polycystic ovary syndrome. The importance of the calpain 10 gene in the pathogenesis of type 2 diabetes seems vary in different populations and ethnic groups and is likely to be the subject of numerous further studies in the coming years.

**Key words:** diabetes, hyperandrogenism, single nucleotide polymorphism.

nucleotide polymorphisms) of the calpain 10 gene, a representative of a large family of cytoplasmic proteases, and development of carbohydrate metabolism disorders, including diabetes, exists [3]. The risk of developing type 2 diabetes is not associated with a variant of a single polymorphism of the gene, but rather results from the haplotypes created by alleles of this gene, which have been numbered 19, 43, 63. All these SNPs are located in introns, they do not have a direct impact on the amino acid structure of the protein, and their importance at the molecular level still requires further studies. However, there is a high probability that they affect the level of gene expression [3, 4]. A possible influence of polymorphisms in the calpain 10 gene on insulin sensitivity is confirmed by the differences in body masses in the groups of carriers of the individual haplotypes [5]. The importance of the calpain 10 gene in the pathogenesis of type 2 diabetes seems to vary in different populations and ethnic groups and is likely to be the subject of numerous further studies in the coming years. In Mexican Americans, this gene appears to be responsible for 14% of cases of type 2 diabetes, while in the population of the United Kingdom, this percentage is approximately 6% [3, 6]. It is interesting that statistical evidence supports the fact that there is a relationship between the calpain 10 gene located on chromosome 2 and a still unidentified gene present on chromosome 15 [3, 7]. An indirect confirmation of the pathogenic role of calpain 10 in type 2 diabetes is the fact that during treatment with protease inhibitors, glucose intolerance developed in patients with AIDS [8]. The mechanism of impaired glucose tolerance associated with the calpain 10 gene has not been yet explained. Calpains are a large family of intracellular proteases participating in the decomposition of other proteins; they can also activate and modulate the activity of other enzymes [9]. Calpains have two key domains exhibiting different metabolic functions. The first of these domains has endoproteinase activity, while the second one – calmodulin, having the ability to bind calcium ions. Therefore, the activity of calpains is controlled by intracellular calcium concentration, although there is also evidence of a direct stimulatory effect of 1,25-dihydroxyvitamin D₃ on their activity [10]. Most of the proteins of the calpain family are expressed in all tissues of the human body, which indicates their importance in maintaining essential cellular functions. There is evidence for the role of these proteins in the pathophysiology of certain diseases in humans. It is believed that their activity affects the extent of necrosis in acute ischemia of the central nervous system. Calpain inhibitors reduce postischemic changes in the brain, which potentially creates the possibility of their use in humans. Calpains were also demonstrated to affect the apoptosis process. It is probably that a high activity of calpains plays a role in the pathogenesis of Alzheimer’s disease [9]. To summarize, recent reports on the role of the calpain 10 gene in the pathogenesis of type 2 diabetes constitutes very interesting scientific material. Although numerous questions are still waiting for answers, it is already possible to say that this is a true scientific breakthrough concerning not only the genetic background and pathogenesis of type 2 diabetes, but also of other diseases of a complex nature. The relationship between the encoding of cysteine in the calpain 10 gene and the occurrence of insulin resistance and type 2 diabetes has been emphasized [11, 12]. In PCOS and type 2 diabetes, there are many common etiological factors [13]. The occurrence of the relationship (p = 0.027) between SNP43 polymorphism of the calpain 10 gene and the risk of PCOS development in Chilean women has been reported [14]. Similar results were obtained by other researchers in a group of women in Brazil [15]. Spanish researchers observed a relationship between the occurrences of PCOS and UC SNP-44, but not UC SNP-43 polymorphism [16]. Similarly, American researchers did not demonstrate a relationship between the occurrence of PCOS and UC SNP-43 [17]. A study of British researchers demonstrated no relationship between PCOS and UC SNP-43 and UC SNP-44 [18]. There is data confirming a relationship between UC SNP-43 and an increased risk of development of type 2 diabetes and metabolic syndrome in diabetes [15, 19]. A relationship between various UC SNP-43 and UC SNP-44 and lipid metabolism disorders in women with PCOS without diabetes [20, 21] was also reported. Numerous studies demonstrated a relationship between polymorphism of the calpain 10 gene and the occurrence of metabolic disorders in PCOS [22–24]. Tkac et al. evaluated the effect of the calpain gene on the efficacy of treatment in 6-month metformin therapy in a study which involved 148 people with type 2 diabetes [25]. They found that the presence of G allele affects the reduction of glycated hemoglobin less that the presence of A allele. The study of Arslan et al. also confirmed the relationship between the presence of haplotype 121 and 122/121 haplotype of SNP-19, -44 and -63 of the calpain 10 gene and the development of type 2 diabetes in the Turkish population [26]. A study performed on a Kurdish ethnic group originating from the western part of Iran also demonstrated the relationship between SNP-43, but not SNP-19, -63, and the development of type 2 diabetes [27]. The role of polymorphism of the calpain 10 gene was the subject of many scientific discussions. It was demonstrated that the calpain 10 gene is involved in molecular mechanisms which increase the risk of the development of type 2 diabetes [28]. Based on the performed meta-analysis of 11 scientific studies, Huang et al. demonstrated a relationship between a polymorphism of the calpain 10 gene and the development of PCOS [29]. Calpain 10 gene polymorphism may be responsible not only for the development of carbohydrate metabolism disturbances, but also for phenotypic characteristics, such as hirsutism. It is not entirely clear whether calpain 10 polymorphism may affect the development of gestational diabetes [30]. A meta-analysis, which included a total of 623 women with PCOS, demonstrated a relationship between calpain 10 polymorphism and the development of PCOS. The most common haplotype, TG3AGCA, was associated with a lower risk of PCOS development (OR = 0.487, p = 0.0057), while the TGA2AGCA haplotype increased the risk of PCOS development (OR = 3.557, p = 0.0011) [31]. The study of Shibli et al., which involved 250 women with PCOS and 299 women in a control group from the region of southern India, demonstrated that the presence of SNP-56 and SNP-19 was associated with a protective role towards PCOS development [32]. At the same time, a twofold higher incidence of PCOS in SNP-44 and SNP-19 (p = 0.03) female carriers was demonstrated.

Analysis of the relationship between gene polymorphism and the risk of PCOS development is still a current issue. The pathogenesis of PCOS, which has not been fully explained, determines the search for new aspects of development of this disease entity. A relationship between polymorphism of the luteinizing hormone receptor and the development of PCOS was demonstrated [33]. In women with TT genotype, higher concentrations of total testosterone, triglycerides and LDL cholesterol were found. No relationship between gene polymorphism in the insulin receptor and the risk of PCOS development was found [34]. A relationship between IL-6 gene polymorphism and the development of PCOS was demonstrated [35]. The study of Radavelli-Bagatini revealed a relationship between adiponectin gene polymorphism and a tendency to hypertension, as well as the development of PCOS, which was confirmed in other studies [36–38]. However, the reports on this subject are contradictory. Other researchers did not demonstrate a relationship between adiponectin gene polymorphism and the development of PCOS, while a relationship between resistin gene polymorphism and PCOS was found [39].
In conclusion, it should be stated that PCOS is a disease entity with a wide spectrum of phenotypes and a complex, multi-component etiology, which still leaves many questions. Until then, the same time, a wide field for scientific activities. In PCOS and type 2 diabetes, there are many common etiological factors. In many studies, researchers have emphasized the existence of a relationship between calpain 10 gene polymorphism and the development of PCOS in many differentiated populations of women. The described disease entity, because of the coexistence of hormonal disorders, infertility, metabolic disorders and sexual dysfunctions, comprises health problems which require an interdisciplinary approach. The group of specialists involved in the diagnostics and treatment of women with PCOS comprises endocrinologists, gynecologists, hypertensologists and sexologists. Because of the prevalence of PCOS and concomitant metabolic disorders, this also constitutes a challenge in the practice of a family doctor.

**References**


34. Bagheri M, Abdi-Rad I, Hosseini-Jazani N, et al. An Association study between INSR/Nsil (rs2059806) and INSR/PmlI (rs1799817) SNPs in women with polycystic ovary syndrome from West Azerbaijan Province, Iran. J Reprod Infertil 2015; 16(2): 109–112.


